VentriPoint Diagnostics Ltd. (VPTDF) Pursues European and Canadian Approvals for New Non-Specific Heart Disease Application
Today before the opening bell, VentriPoint Diagnostics announced it has filed for CE Mark and Health Canada approvals for its database for non-specific heart disease (NRV). By using this database, clinicians can rapidly and accurately assess the status of the right ventricle (RV) in all patients that do not have significant congenital heart defects or Pulmonary Arterial Hypertension (PAH), yet may have a variety of other conditions, such as left-heart failure or valve disease. "Our customers have asked for the NRV application so they can assess the RV in virtually every patient they see," said Dr. George Adams, CEO of…